Skip to content

Long-Term Outcomes of Dydrogesterone in Postoperative Endometriosis:A Real-World Study

Long-Term Outcomes of Dydrogesterone in Postoperative Endometriosis:A Real-World Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103211
Enrollment
Unknown
Registered
2025-05-27
Start date
2025-06-30
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

Experimental group:Dydrogesterone

Sponsors

Women’s Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1) Female, aged>=18 years and<=45 years, and signed an informed consent form; 2) Patients diagnosed with endometriosis after surgery; 3) Patients who are willing to receive long-term management of levonorgestrel after surgery; 4) Within the first 3 months of participating in this study, no other hormone therapy for endometriosis was received. 5) Patients with good compliance and cooperation in follow-up;

Exclusion criteria

Exclusion criteria: 1) Symptoms such as pelvic pain and vaginal bleeding caused by unknown reasons or reasons other than endometriosis; 2) Known or suspected malignant tumors; 3) Postoperative treatment with other hormone or GnRH-a drugs for endometriosis; 4) Personnel who are currently using other drugs that interact with the investigational drug and cannot stop taking the drug will be informed in detail of their medication situation, and the researchers will make a judgment for them; 5) Patients with severe heart, liver, and kidney diseases, as well as those with adrenal cortex dysfunction; 6) Patients with active digestive ulcers or drug allergies or allergic constitutions; 7) Participated in other clinical trials within 3 months; 8) Those with fertility needs; 9) And factors that other personnel believe you are not suitable to participate in the experiment.

Design outcomes

Primary

MeasureTime frame
The recurrence rate of endometriosis cysts after 12 months of postoperative medication;

Secondary

MeasureTime frame
Quality of life;Menstrual changes;The recurrence rate of pain (pelvic pain, dysmenorrhea, painful intercourse);The recurrence rate of endometriosis cysts after 24 months of postoperative medication;Liver function, coagulation function, blood lipids;

Countries

China

Contacts

Public ContactXinmei Zhang

Women’s Hospital, Zhejiang University School of Medicine

zhangxinm@zju.edu.cn+86 571 89992111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026